When You Can't Get Anakinra, You Need a Plan B

Maybe your pharmacy can't get it. Maybe insurance denied your prior authorization. Maybe the cost — roughly $1,500 to $6,000+ per month without insurance — simply isn't workable right now. Whatever the reason, if you can't fill your Anakinra (Kineret) prescription, you need to know what other options exist.

Let's be clear: never stop or switch medications without talking to your doctor first. But it's worth understanding the landscape so you can have an informed conversation with your prescriber.

What Is Anakinra and How Does It Work?

Anakinra is a biologic medication that belongs to a class of drugs called interleukin-1 (IL-1) receptor antagonists. It works by blocking the IL-1 receptor on your cells, which prevents the inflammatory proteins IL-1 alpha and IL-1 beta from triggering inflammation.

It's FDA-approved for:

• Rheumatoid arthritis (after other DMARDs have failed)
• NOMID/CAPS (Neonatal-Onset Multisystem Inflammatory Disease / Cryopyrin-Associated Periodic Syndromes)
• DIRA (Deficiency of Interleukin-1 Receptor Antagonist)

Doctors also use it off-label for acute gout, recurrent pericarditis, Still's disease, and other autoinflammatory conditions. To learn more about the medication itself, see our full guide: What is Anakinra? Uses, dosage, and what you need to know.

Alternative 1: Canakinumab (Ilaris)

Canakinumab, sold as Ilaris, is a monoclonal antibody that specifically targets and neutralizes IL-1 beta. It's in the same therapeutic family as Anakinra but works differently — it binds directly to the IL-1 beta protein rather than blocking the receptor.

FDA-approved for:

• Cryopyrin-Associated Periodic Syndromes (CAPS), including FCAS and Muckle-Wells Syndrome
• Systemic Juvenile Idiopathic Arthritis (SJIA)
• Familial Mediterranean Fever (FMF)
• Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)
• Hyperimmunoglobulin D Syndrome (HIDS/MKD)

Key differences from Anakinra:

• Given as a subcutaneous injection every 4 to 8 weeks instead of daily — a major convenience advantage
• Significantly more expensive — often $15,000-$20,000+ per injection
• Not FDA-approved for rheumatoid arthritis
• Longer half-life means longer-lasting effects, but also slower to clear if side effects occur

Alternative 2: Rilonacept (Arcalyst)

Rilonacept, sold as Arcalyst, is an IL-1 trap — a fusion protein that acts like a decoy receptor, binding and neutralizing both IL-1 alpha and IL-1 beta before they can reach your cells.

FDA-approved for:

• Cryopyrin-Associated Periodic Syndromes (CAPS), specifically FCAS and Muckle-Wells Syndrome
• Recurrent pericarditis (FDA-approved in 2021 — the first drug specifically approved for this condition)

Key differences from Anakinra:

• Given as a weekly subcutaneous injection instead of daily
• Particularly strong option if your condition is recurrent pericarditis
• Not FDA-approved for rheumatoid arthritis or DIRA
• Also a high-cost specialty biologic

Alternative 3: Colchicine (for Gout and Pericarditis)

If you're taking Anakinra off-label for acute gout or recurrent pericarditis, Colchicine is a much more accessible and affordable alternative. It's an anti-inflammatory medication that's been used for centuries.

Key points:

• Oral tablet — no injections needed
• Generic versions available for as little as $10-$30 per month
• FDA-approved for gout flares (Colcrys, Mitigare) and used in pericarditis
• Very different mechanism of action — inhibits tubulin polymerization and reduces inflammatory cell activity
• Not appropriate for CAPS, DIRA, NOMID, or RA

Alternative 4: TNF Inhibitors (for Rheumatoid Arthritis)

If you're taking Anakinra specifically for rheumatoid arthritis, your doctor may consider switching to a TNF inhibitor — a different class of biologic that is much more commonly used for RA. These include:

• Adalimumab (Humira) — now available as lower-cost biosimilars
• Etanercept (Enbrel) — weekly injection, also has biosimilars
• Infliximab (Remicade) — IV infusion, multiple biosimilars available
• Certolizumab (Cimzia)
• Golimumab (Simponi)

Important: TNF inhibitors should never be combined with Anakinra due to a significantly increased risk of serious infections. This is an either/or choice, not both.

TNF inhibitors are generally more widely available and have more biosimilar options, which can make them easier to access and less expensive.

How to Decide: Talk to Your Doctor

The right alternative depends entirely on why you're taking Anakinra. A patient with CAPS has very different options than someone with rheumatoid arthritis or pericarditis. Here's a quick framework:

• CAPS/NOMID/DIRA: Canakinumab or Rilonacept are the closest alternatives
• Rheumatoid arthritis: TNF inhibitors are typically the next option
• Gout or pericarditis: Colchicine or Rilonacept may be appropriate
• Still's disease: Canakinumab or TNF inhibitors depending on disease activity

Before switching, make sure to discuss drug interactions and side effects with your doctor.

Final Thoughts

Not being able to fill your Anakinra prescription is stressful, but you're not out of options. Whether the barrier is supply, insurance, or cost, there are alternatives that your doctor can consider.

Before exploring a switch, try these resources first:

• Medfinder — to check pharmacy stock near you
• Our cost-saving guide — for coupons, copay assistance, and patient assistance programs
• Our stock-finding guide — for tips on locating Kineret at specialty pharmacies

Sometimes the solution is finding the drug, not replacing it.